Cas:5435-31-4 1H-benzimidazole-2-sulfonamide manufacturer & supplier

Chemical Name:1H-benzimidazole-2-sulfonamide

CAS.NO:5435-31-4

Synonyms:benzimidazole-2-sulfonamide;1H-Benzimidazol-2-sulfonamid;2-Benzimidazolesulfonamide;1H-1,3-benzodiazole-2-sulfonamide;1H-benzoimidazole-2-sulfonic acid amide;Benzimidazol-2-sulfonamid

Molecular Formula:C₇H₇N₃O₂S

Molecular Weight:197.21400

HS Code:2935009090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:492.9ºC at 760 mmHg

Density:1.589g/cm3

Index of Refraction:1.71

PSA:97.22000

Exact Mass:197.02600

LogP:1.99140

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like benzimidazole-2-sulfonamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzimidazol-2-sulfonamid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzimidazol-2-sulfonamid Use and application,2-Benzimidazolesulfonamide technical grade,usp/ep/jp grade.

Related News: Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients. 1H-benzimidazole-2-sulfonamide manufacturer Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. 1H-benzimidazole-2-sulfonamide supplier The purpose of APIs according to the FDA is to cause ��pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the human body. 1H-benzimidazole-2-sulfonamide vendor Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates. 1H-benzimidazole-2-sulfonamide factory Dr. John K. Westwick, CEO of Resonant, added ��Resonant has created a platform for rapid generation of novel anti-tumor antibody candidates.